News
Outline of New Cleveland Clinic Brain Study: Imad Najm, MD
February 10th 2022The director of Cleveland Clinic’s Epilepsy Center provided insight on a new 20-year initiative to uncover more about the origins of neurological diseases and how they occur prior to symptom onset. [WATCH TIME: 3 minutes]
Deep Learning Algorithm Shows High Accuracy in Predicting ICH Hematoma Expansion
February 10th 2022The artificial neural network demonstrated an area under the precision-recall curve of 0.92 with recall of 0.72 with precision of 0.39 during testing, all values that were greater than classic regression models.
Prime PD: A New Virtual Fitness Program for Parkinson Disease: Konstantin Karmazin, MD
February 10th 2022The chief medical officer of Prime PD spoke on motivations behind the development of the program and the unique benefits it offers amidst the ongoing COVID-19 pandemic. [WATCH TIME: 3 minutes]
Understanding the Epidemiological Connection Between MS and Epstein-Barr Virus: AJ Joshi, MD
February 9th 2022The chief medical officer at Atara Biotherapeutics detailed the clinical significance of a recently published paper in Nature that adds to the evidence that Epstein-Barr virus is the leading cause of multiple sclerosis. [WATCH TIME: 3 minutes]
Racial Subgroup Data Heavily Underreported in MS Trials, Lack of Non-White Representation
February 9th 2022Almost 40% of the studies assess did not report racial or ethnic subgroup data. Geographically, there was a slight increase in the number of South American-based phase 3 DMT trials and almost little-to-no improvement in the phase 3 DMT studies based in Africa.
NeuroVoices: Imad Najm, MD, on Aiming to Prevent Neurological Disorders Before Symptom Onset
February 9th 2022The director of Cleveland Clinic’s Epilepsy Center discussed the new Cleveland Clinic Brain Study, which will evaluate predisease fingerprints from patients who go on to develop neurological disorders.
Evaluating Sigma-2 Receptor Modulators as Prospective DMTs for Parkinson Disease
February 8th 2022Having recently been awarded a grant from the Michael J. Fox Foundation, Mary Hamby, PhD, VP of research at Cognition Therapeutics, and Lisa Ricciardi, the company’s CEO, sat down to discuss the potential disease-modifying effects for this patient population.
Future Research on the Pathogenesis of COVID-19, Cognitive Changes: Joanna Hellmuth, MD, MS
February 8th 2022The cognitive neurologist at the University of California San Francisco discussed the need to continue research on why patients develop cognitive changes following COVID-19 infection and how clinicians can care for them. [WATCH TIME: 4 minutes]
Optimizing Integrative Wellness Strategies for MS Through Research: Kathy Zackowski, PhD, OTR
February 6th 2022The senior director of patient management, care, and rehabilitation at the National Multiple Sclerosis Society discussed the steps needed to take to improve relatively new wellness strategies. [WATCH TIME: 3 minutes]
Sleep Disorders Prevalent in Children With Tuberous Sclerosis Complex
February 5th 2022Investigators noted that while epilepsy did not increase the risk for sleep disorders, there was a strong association identified with TSC-association neuropsychiatric disorders, necessitating early detection.
Anavex Provides Update on Blarcamesine, Phase 3 AVATAR Trial Addressing Concerns
February 5th 2022After changes were made to the AVATAR phase 3 study in Rett syndrome, Anavex provided context on the timing of the adjustments, which were approved by regulatory bodies in the UK and Australia, where the trial was conducted.
The Potential of Risdiplam for Presymptomatic Babies With SMA Under 2 Months
February 4th 2022Matthew Klein, MD, MS, FACS, the COO of PTC Therapeutics, discussed a supplemental new drug application for the treatment in a younger group of patients, which has been granted priority review by the FDA.
